Results 151 to 160 of about 2,776,276 (310)

Engineering programmable peptide hydrogels for chronic refractory wounds: A mechanism‐driven framework

open access: yesBMEMat, EarlyView.
To break the self‐perpetuating pathology of chronic wounds, we propose a mechanism‐driven engineering framework for peptide‐based hydrogels. This review elucidates a hierarchical strategy—from molecular design to intelligent, multi‐functional systems—that enables these programmable biomaterials to dynamically intervene in key pathological loops and ...
Xiaoyu Lv   +3 more
wiley   +1 more source

Digital workflow to assess healing after acellular dermal matrix exposure in root coverage: A case report

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background This case report describes 18‐month clinical and digital outcomes after bilateral treatment of multiple gingival recessions using coronally advanced flap plus acellular dermal matrix (ADM). Methods A 46‐year‐old woman with multiple maxillary recessions received bilateral surgery.
Edgar Daniel Vargas‐Quiroga   +7 more
wiley   +1 more source

Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug‐Induced Liver Injury: A Multicentric Propensity Scores Matched Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clinical significance of acute kidney injury in idiosyncratic drug‐induced liver injury: a multicentric propensity scores matched study. Evidence about the role of acute kidney injury (AKI) in idiosyncratic drug‐induced liver injury (DILI) is still scarce.
José María Pinazo‐Bandera   +15 more
wiley   +1 more source

Supplementary table for Dermal hypersensitivity reaction masquerading as cellulitis: an underrecognized diagnostic pitfall in the inpatient setting

open access: yes
This dataset include the supplemental table for Dermal hypersensitivity reaction masquerading as cellulitis: an underrecognized diagnostic pitfall in the inpatient ...
Hong, Suyeon
core   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu   +15 more
wiley   +1 more source

Hypersensitivity reaction to etoposide. A case report [PDF]

open access: yesFarmacia Hospitalaria, 2014
M. Mullera Martí   +3 more
doaj   +1 more source

Confirmed Multiple Drug Hypersensitivity Syndrome is Uncommon, and its Culprit Drug Spectrum Reflects Patterns of Drug Exposure

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Multiple drug hypersensitivity syndrome (MDHS) is defined as confirmed hypersensitivity to two or more chemically and pharmacologically unrelated drug entities. Few studies have characterized MDHS with systematic diagnostic confirmation. We aimed to determine the frequency, culprit drug patterns, and diagnostic findings of confirmed MDHS.
Da Woon Sim, Ji Eun Yu, Young‐Il Koh
wiley   +1 more source

Delayed Hypersensitivity Reaction to Insulin: A Case Report. [PDF]

open access: yesCureus
Aharmim M   +3 more
europepmc   +1 more source

Transforming Growth Factor‐β (TGF‐β)–Dependent Iron Homeostasis and Altered TGF‐β Responsiveness in FLVCR1‐Deficient CD4 T Cells

open access: yesBarrier Immunity, EarlyView.
Negative feedback resulting from continuous TGFβRI expression in FLVCR1‐deficient CD4 T cells. Unlike in normal CD4 T cells, TGF‐βRI is not degraded upon activation in FLVCR1‐deficient CD4 T cells. Sustained receptor expression results in increased TGF‐β, leading to dysregulated iron homeostasis, impaired cell proliferation, and enhanced cell death ...
Amber L. Siglin   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy